Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation has recently completed a Phase 1 ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi ...

Incyte (NASDAQ:INCY) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.In the table below, you'll find a summary of their recent ...

Incyte has launched the Vitiligo Innovators Program to honor exceptional individuals who have made significant contributions to the vitiligo community, according to a company press release. Noted ...

Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial By Nick Paul Taylor Mar 11, 2024 7:16am Incyte clinical trial data JAK inhibitors Dermatology ...

Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry ’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame. The ...